Phase I double-blind randomized control study evaluate safety and immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 recombinant malaria vaccine (PfCP-2.9) adjuvant with montanide ISA 720 compared to montanide ISA 720 alone in adult volunteers

Trial Profile

Phase I double-blind randomized control study evaluate safety and immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 recombinant malaria vaccine (PfCP-2.9) adjuvant with montanide ISA 720 compared to montanide ISA 720 alone in adult volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs Malaria vaccine (Primary) ; Montanide ISA-720
  • Indications Falciparum malaria; Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Shanghai Wanxing Bio-Pharmaceutical
  • Most Recent Events

    • 09 Dec 2008 Results were published in Vaccine.
    • 04 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top